Eribulin mesylate in the treatment of metastatic breast cancer

Sarika Jain, Tessa Cigler*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

23 Scopus citations

Abstract

The treatment of metastatic breast cancer (MBC) has become increasingly challenging as the primary goals of therapy include prolonging life without added toxicity. While multiple agents are approved for the therapy of MBC, there is no standard approach for therapy beyond the second-line. Eribulin mesylate, an analog of the marine sponge halichondrin B, is a non-taxane microtubule dynamics inhibitor with a mechanism of action distinct from other tubulin-targeted drugs. Based on a significant extension in overall survival seen in a Phase III clinical trial, eribulin was approved for third-line therapy in MBC patients following anthracycline and taxane failure. Eribulin has a manageable toxicity profile and a low incidence of peripheral neuropathy. In this review, we discuss the natural source of eribulin, pharmacology, mode of action, preclinical and clinical data, and patient-focused perspectives.

Original languageEnglish (US)
Pages (from-to)21-29
Number of pages9
JournalBiologics: Targets and Therapy
Volume6
StatePublished - Feb 10 2012

Keywords

  • Eribulin
  • Metastatic breast cancer
  • Microtubule

ASJC Scopus subject areas

  • Immunology and Allergy
  • Rheumatology
  • Oncology
  • Gastroenterology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Eribulin mesylate in the treatment of metastatic breast cancer'. Together they form a unique fingerprint.

Cite this